Developing polyphenolic acetates as radiation countermeasure agents: current status and future perspectives
| Autor: | Kavya Venkateswaran, Virinder S. Parmar, Ashok K. Prasad, Anju Shrivastava, Bilikere S. Dwarakanath |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
0301 basic medicine
Oncology medicine.medical_specialty Radiation-Protective Agents Mice 03 medical and health sciences 0302 clinical medicine Drug Development Coumarins Internal medicine Drug Discovery medicine Animals Humans Radiation injury Pharmacology business.industry Polyphenols Acute Radiation Syndrome Mice Inbred C57BL Disease Models Animal Radiation Injuries Experimental 030104 developmental biology 030220 oncology & carcinogenesis business Countermeasure (computer) |
| Zdroj: | Drug Discovery Today. 25:781-786 |
| ISSN: | 1359-6446 |
| DOI: | 10.1016/j.drudis.2020.02.004 |
| Popis: | Total-body exposure to ionizing radiation (TBI) results in life-threatening acute radiation syndrome (ARS), which encompasses hematopoietic and gastrointestinal (GI) injuries and results in dose-dependent morbidity and mortality. Management of ARS warrants the deployment of effective medical countermeasure agents (MCM) that protect against and/or mitigate lethal radiation injury. The polyphenolic acetate (PA) 7,8-diacetoxy-4-methylthiocoumarin (DAMTC) has been identified as a potential MCM against ARS by virtue of it mitigating the lethal effects of TBI in C57BL/6 mice. Herein, we describe current evidence, including mechanistic aspects, for the use of PAs as MCMs against ARS and provide perspectives for their further development as approved drugs for the mitigation of ARS. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect